Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cigna (CI) remains well-poised for growth on the back of improved pharmacy revenues in its Evernorth unit. Solid cash-generating abilities also enable it to tactically deploy capital.

Compelling Reasons to Hold on to Cigna (CI) Stock for Now

BEAUFORT, S.C.--(BUSINESS WIRE)--OptiFuel's Zero Emission Locomotives fueled by RNG = lower cost than diesel. Their pioneering Locomotive-as-a-Service (LAAS™) Program = affordability.

Zero Emission Line Haul Locomotives for $1.1 Million? OptiFuel Puts Renewable Fuel Credits to Smart Use for the Benefit of US Railroads

The Cigna Group (NYSE:CI ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 10:00 AM ET Company Participants Brian Evanko - CFO Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Good morning, everyone.

The Cigna Group (CI) Management presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

Cigna Group's dividend growth potential and strong financial performance make it worth considering for long-term investors. The company's revenue for the quarter grew by 23.3% year over year, with strong growth in its Evernorth Health Services segment. Management's outlook projects a 6% to 9% estimated growth rate for the company, with potential for increased market share and higher revenues.

Cigna: Will Benefit From Lower Medicaid Enrollments

UnitedHealth Group

Cigna's CFO Brian Evanko said the company's "outpatient dynamic" was impacted by the Change Healthcare hack which disrupted claims during the first quarter of 2024.

UnitedHealth hack impacted outpatient claims for Cigna - GS conference

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023.

Is Cigna Group the Nation's Best-Run Health Insurance Company?

PARIS--(BUSINESS WIRE)--OpsMill, a pioneer in infrastructure and network automation, today announced the beta release of its open source Infrahub platform. Infrahub unifies previously disparate automation capabilities into a single platform, enabling IT teams to transform all their data center, cloud, network, and security infrastructure operations with scalable and consumable automation. “I've spent years building automation systems for infrastructure and network management across a variety of.

OpsMill Transforms Infrastructure Automation with Beta Release of Open Source Infrahub

Cigna's (CI) Express Scripts collaborates with CPESN USA in a bid to enhance care delivery for hypertension and diabetes patients.

Cigna's (CI) Express Scripts Collaborates With CPESN USA

Based on guidance from its Independent Pharmacy Advisory Committee, Express Scripts will collaborate with CPESN  ®  USA through its IndependentRx initiative ST. LOUIS , May 23, 2024 /PRNewswire/ -- Express Scripts, the pharmacy benefits services business of The Cigna Group's (NYSE: CI) Evernorth, is making it easier for people to access a broader range of care services at independent pharmacies.

Express Scripts enhances strategies to support access to care at independent pharmacies

BLOOMFIELD, Conn. , May 21, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Brian Evanko, EVP and CFO of The Cigna Group, President and CEO of Cigna Healthcare, will present at Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami, FL.

The Cigna Group Announces Appearance at Goldman Sachs 45th Annual Global Healthcare Conference

Broadcom

Bank of America

Brown & Brown

Carlisle Companies

Dick's Sporting Goods

Comfort Systems USA

Hess Midstream Partners

Imperial Oil

Lennar

Martin Marietta Materials

Microsoft

NRG Energy

Owens Corning

Quanta Services

QUALCOMM

Target

Tesco PLC

Wingstop

This article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The article provides criteria for selecting high-growth dividend stocks. It offers a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Dividend Growth Stocks - May 2024

Amazon

Alibaba

Baidu

Citigroup

First Solar

GEN Restaurant Group Inc

Alphabet

HCA Healthcare

JD.com

MGM Resorts

Warner Bros Discovery Inc

Back in February, the filing of the 13-f document for Michael Burry's Scion Asset Management caused quite a stir as it revealed that ‘ The Big Short ' investor had not only given up on his large bet against the semiconductor industry but also tool more than a dozen long positions during the final trimester of 2023.

Here's Michael Burry's updated stock portfolio

The Cigna Group (NYSE:CI ) BofA Securities 2024 Health Care Conference Call May 15, 2024 2:40 PM ET Company Participants Brian Evanko - CFO of The Cigna Group, President and CEO of Cigna Healthcare Hasan Riaz - Lead Principal, Investor Relations Ralph Giacobbe - Head of Investor Relations Conference Call Participants Kevin Fischbeck - Bank of America Kevin Fischbeck All right. I want to thank everyone for joining us today.

The Cigna Group (CI) BofA Securities 2024 Health Care Conference Call Transcript

Though Cigna Group  (NYSE:CI) stock was last seen down 1% to trade at $343.11, it's not too far removed from its March 28, record high of $365.71, and sports a 34.6% year-over-year lead.

Cigna Stock Ready to Bounce Off Bullish Trendline

Overall ranking increased seven spots from 2023, reflecting the enterprise's actions to bolster the vitality of The Cigna Group's workforce and the communities it serves BLOOMFIELD, Conn. , May 14, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) announced today that it is No.

The Cigna Group Ranks No. 7 in Fair360 Top 50 Companies

Cigna doesn't yet have the established dividend growth track record that I like to see, but it has everything else. The company's total revenue and non-GAAP EPS each surpassed analysts' expectations in Q1. Cigna's dividend is easily covered by free cash flow and the debt load is manageable.

Cigna: An Up-And-Coming Dividend Growth Stock To Buy Now

Cigna Group exceeded earnings per share (EPS) and revenue estimates. Significant growth in Evernorth and Cigna Healthcare segments fueled performance.

Cigna Tops Q1 Estimates, Raises Forecast

Centene

Humana

The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern.

4 HMO Stocks to Watch Amid Persistent Industry Challenges

Although the revenue and EPS for Cigna (CI) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Cigna (CI) Q1 Earnings: A Look at Key Metrics

Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.

Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit

The Cigna Group (NYSE:CI ) Q1 2024 Earnings Call Transcript May 2, 2024 8:30 AM ET Company Participants Ralph Giacobbe - SVP of IR David Cordani - Chairman and CEO Brian Evanko - CFO, and President and CEO, Cigna Healthcare Eric Palmer - President and CEO, Evernorth Health Services Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - JPMorgan Andrew Mok - Barclays Scott Fidel - Stephens Sarah James - Cantor Kevin Fischbeck - Bank of America A.J. Rice - UBS George Hill - Deutsche Bank Erin Wright - Morgan Stanley Gary Taylor - Cowen Lance Wilkes - Bernstein Operator Ladies and gentlemen, thank you for standing by for the Cigna Group's First Quarter 2024 Results Review.

The Cigna Group (CI) Q1 2024 Earnings Call Transcript

Cigna (CI) came out with quarterly earnings of $6.47 per share, beating the Zacks Consensus Estimate of $6.17 per share. This compares to earnings of $5.41 per share a year ago.

Cigna (CI) Q1 Earnings and Revenues Beat Estimates

Cigna Group's stock CI, +0.04% rose 2.7% early Thursday, after the healthcare and insurance company posted better-than-expected first-quarter earnings and raised its guidance. The company had a net loss of $277 million, or 97 cents a share, for the quarter, after income of $1.267 billion, or $4.24 a share, in the year-earlier period.

Cigna's stock jumps 2.7% after earnings beat estimates and company raises guidance

Health insurer Cigna Group raised its annual profit forecast on Thursday, as lower-than-expected medical costs and strength in its pharmacy benefit management unit helped it beat first-quarter earnings estimates.

Cigna sees strong annual profit on lower costs, pharmacy benefit strength

Total revenues for the first quarter 2024 were $57.3 billion Shareholders' net loss for the first quarter 2024 was $0.3 billion, or $0.97 per share Adjusted income from operations1 for the first quarter 2024 was $1.9 billion, or $6.47 per share 2024 outlook2 for adjusted income from operations1,2 increased to at least $28.40 per share BLOOMFIELD, Conn. , May 2, 2024  /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today reported strong first quarter 2024 results reflecting growth across its diversified portfolio of businesses.

News for Cigna Stock (CI)